CRYAB (αB-crystallin) is a small heat shock protein (sHSP) belonging to the crystallin family, initially identified as a structural component of the eye lens. It functions as a molecular chaperone, preventing protein aggregation under stress conditions like heat, oxidative stress, or ischemia by stabilizing partially unfolded proteins. Beyond the lens, CRYAB is widely expressed in non-ocular tissues, including cardiac and skeletal muscles, brain, and kidneys, where it plays critical roles in maintaining cellular homeostasis, apoptosis regulation, and cytoskeletal integrity.
CRYAB has been implicated in various diseases. Mutations in the CRYAB gene are linked to cataracts and myofibrillar myopathies. Its dysregulation is associated with neurodegenerative disorders (e.g., Alzheimer’s disease), cardiovascular diseases, and cancers. In oncology, CRYAB overexpression in tumors may promote metastasis, chemoresistance, and immune evasion, making it a potential therapeutic target or biomarker.
CRYAB antibodies are essential tools for detecting and quantifying CRYAB expression in research and diagnostics. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study its localization, expression patterns, and interactions in disease models. Commercial CRYAB antibodies vary in host species, clonality, and epitope specificity, requiring rigorous validation for experimental reproducibility. Their applications extend to exploring CRYAB's roles in cellular stress responses, protein quality control, and disease mechanisms, contributing to therapeutic development and diagnostic advancements.